web analytics
10.7 C
Munich
Monday, October 25, 2021

Enzolytics, Inc. (ENZC) Major Breakout as Biotech Gains Traction in Booming HIV Market

Enzolytics, Inc. (ENZC) has emerged in recent weeks as the most exciting stock in small caps that is quickly developing a massive following of investors who are looking to ride this one past its recent 0.958 per share highs well into multi dollar land. ENZC is just now getting noticed by big money investors since the historic merger between BioClonetics and Enzolytics; the new biotech produces fully human monoclonal antibodies currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 but more historically to fight HIV.  

ENZC flagship is called ITV-1, this patented ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in boosting the imune system and controlling HIV/AIDS. ENZC just announced plans to take its ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. The Company’s ITV-1 anti-HIV therapeutic earlier progressed toward certification under the Bulgarian Drug Agency (BDA) but that process was interrupted before completion. However, in that process, significant positive clinical trial results in patients were documented. These positive results give the Company total confidence that the now planned clinical trials under the European Medicines Agency (EMA) will likewise be successful. ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy as Insider Financial recently reported in an outstanding article on ENZC. ITV-1 appears to work across a range of infectious diseases, from coronaviruses to HIV by boosting the immune system and controlling HIV/AIDS most likely acting as a superantigen—inducing polyclonal expansion of T cells and stimulating a broad immune response against the virus, and by binding directly to gp41 and gp120 of the HIV virus. 

Enzolytics Inc (OTCMKTS: ENZC) is a drug development Company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in treating HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system. The Company is also implementing its proprietary technology to produce fully human monoclonal antibodies (mAbs) against infectious diseases, including HIV, rabies, influenza A, influenza B, tetanus, and diphtheria. Its proprietary methodology for producing fully human monoclonal antibodies is currently employed to produce monoclonal antibody therapeutics for numerous infectious diseases, including the Coronavirus (SARS-CoV-2) and HTLV-1. 

ENZC has partnered with Intel to publish a white paper titled, “Optimizing Empathetic A.I. to Cure Deadly Diseases,” highlighting Intel’s Artificial Intelligence Analytic tools and Enzolytic’s innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. This collaborative effort approaches the future of medicine; a future wherein the process of healthcare evolves from reactive to anticipatory, as exemplified by P4 Medicine. The conclusion described in the White Paper is that Enzolytics Inc’s use of Artificial Intelligence underscores a novel approach in assessing millions of virus sequences to identify the conserved segments essential for virus survival. Through effective public and private sector symbiosis and the fostering of a technology-neutral regulatory environment, the genuine power of A.I., coupled with advanced techniques in proprietary technologies illustrated in the Enzolytics immunotherapeutics, will no doubt create universal, durable, and broadly effective treatment targeting all virus variants. This was followed by the news that ENZC has identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). Utilizing the Company’s proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human anti-HTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University’s Institute for Preclinical Studies. The Company’s own Artificial Intelligence team continues to identify the critical sites on viruses against which monoclonal antibodies will be produced to treat infectious viral diseases. 

Microcapdaily has been reporting on the ENZC BioColnetics merger since the beginning recenlty stating: “Enzolytics Inc. ENZC: is making a highly explosive move up the charts recently surpassing $0.50 per share and regularly topping $25 million USD per day in dollar volume ENZC has transformed into a major league runner in small caps. Enzolytics and its new subsidiary BioClonetics own licensing rights of the Irreversible Pepsin Fraction peptide molecule for the treatment of HIV/AIDS a market expected to be worth $30 billion plus by 2025. The Company produces targeted (nontoxic) monoclonal antibodies and is now advancing two separate but complementary therapy platforms for treating infectious diseases, targeting HIV and the CoronaVirusEnzolytics has attracted a major league level management team behind it and has expanded its lab capabilities on the Texas A&M University campus at the Institute for Pre-clinical Studies, where it is producing both addition monoclonal antibodies against HIV and the against covid-19. This expansion allows Enzolytics to complete the production of monoclonal antibodies against both the HIV virus and the coronavirus and collaborate with the biopharma experts on the campus. Microcapdaily first reported on ENZC the day after the merger was announced in our article: “BioClonetics LOI Sparks Enzolytics Inc (OTCMKTS: ENZC)” on September 16 when ENZC was trading for well under $0.01  

Enzolytics has quickly attracted a power house team behind it which speaks of big things to come here. They recently appointed Ronald Moss, M.D., to the Medical Advisory Board. Mr. Moss has been an executive with numerous biotech’s over the past 25 years. He has extensive clinical and regulatory management expertise in guiding programs through Phase I, II, and III clinical trials, including IND and NDA experience. The Company’s Chief Science Officer, Mr. Henry Zhabilov has managed several clinical trials utilizing therapeutic proteins. He is the inventor of several U.S. patents related to the immunotherapy of HIV and cancer and an immune enhancer based on the company’s IPF platform. 

To Find out the inside Scoop on ENZC Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

ENZCOn June 14 ENZC announced it has concluded definitive plans to advance its previously tested ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. Completion of these steps will establish its anti-HIV therapy as a significant revenue source for the Company, a meaningful milestone for both human health and Company profitability. The Company’s ITV-1 anti-HIV therapeutic earlier progressed toward certification under the Bulgarian Drug Agency (BDA) but that process was interrupted before completion. However, in that process, significant positive clinical trial results in patients were documented. These positive results give the Company total confidence that the now planned clinical trials under the European Medicines Agency (EMA) will likewise be successful. 

The steps now in place to accomplish the Company’s goal of bringing its anti-HIV ITV-1 therapeutic to patients are: The Company has formed International Medical Partners Ltd. (IMPL) in partnership with European partners. IMPL is owned equally by the Company and its partners and has the licenses to distribute the ITV-1 therapeutic in the 27 European countries covered by the European Medical Agency plus Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia and Lithuania. 

The Company has engaged the Contract Manufacturing Company (CMO) Danhson Ltd. to produce the initial quantity of ITV-1 used in preparing the required Best Methods Report for future production and clinical trials documentation.The Company has engaged the Contract Research Organization (CRO) Clinical Design Ltd. in cooperation with PharmaLex to prepare and establish a drug development programme concerning creation of protocols for human clinical trials that will lead to the licensing of the Company’s ITV-1 therapeutic under the European Medicine Agency (EMA). The production at Danhson Ltd. will produce initial quantities of the therapeutic to be used for completion of preclinical testing and then initiating clinical trials with Clinical Designs, Ltd. MBL is contracting with PharmaLex, a leading EU regulatory consulting company to manage document review of the product compliance with EMA requirements. 

CEO Charles Cotropia said, “The Company’s objective is to provide new, better and safer therapeutics to treat HIV. Currently, treatment is solely through the lifelong use of antiretrovirals (ARVs) which are expensive and have long lasting, serious negative effects on the body. The costs for such ARVs are excessive – from $27,540 per year for Dovato by ViiV/Glaxo SmithKline to $42,635 per year for Biktarvy by Gilead and a lifetime costs of up to $350,000 – and even then, only 54% of those ineffective by HIV have access to such treatments – leaving 46% with no treatment. New and improved therapies, that are less expensive and more effective, are desperately needed. Providing these better therapies are our Company’s objective.” 

https://twitter.com/Dr_Stonky/status/1409545986918305801

For more on ENZC Subscribe Right Now!

Enzolytics has emerged in recent weeks as the most exciting stock in small caps that is quickly developing a massive following of investors who are looking to ride this one past its recent 0.958 per share highs well into multi dollar land. ENZC is just now getting noticed by big money investors since the historic merger between BioClonetics and Enzolytics; the new biotech produces fully human monoclonal antibodies currently being employed to produce anti-SARS-CoV-2 (CoronaVirus) monoclonal antibodies for treating COVID-19 but more historically to fight HIV. ENZC flagship is called ITV-1, this patented ITV-1 (Immune Therapeutic Vaccine-1) is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in boosting the imune system and controlling HIV/AIDS. ENZC just announced plans to take its ITV-1 anti-HIV therapeutic to clinical trials and distribution throughout Europe. The Company’s ITV-1 anti-HIV therapeutic earlier progressed toward certification under the Bulgarian Drug Agency (BDA) but that process was interrupted before completion. However, in that process, significant positive clinical trial results in patients were documented. These positive results give the Company total confidence that the now planned clinical trials under the European Medicines Agency (EMA) will likewise be successful. ENZC could become a major player in the enormous $30 billion annual HIV market expected to reach $37 billion in the next 5 years. In a market primarily controlled by Gilead who sold $17 billion in HIV drugs last year Enzolytic’s HIV treatment is immunotherapy, not chemotherapy as Insider Financial recently reported in an outstanding article on ENZC. ITV-1 appears to work across a range of infectious diseases, from coronaviruses to HIV by boosting the immune system and controlling HIV/AIDS most likely acting as a superantigen—inducing polyclonal expansion of T cells and stimulating a broad immune response against the virus, and by binding directly to gp41 and gp120 of the HIV virus.  Microcapdaily first reported on ENZC on September 16 when  the stock was well below a penny. We will be updating on ENZC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with ENZC.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in ENZC either long or short and we have not been compensated for this article.

More articles

3 COMMENTS

  1. Nice Article, but it didn’t mention its other Premiere Patent: Clone3, which is so valuable Dr. Fauci tried to steal it in 1998, falsely claming he invented it, but US Patent Examiner ruled in favor of the true inventor, Dr. Joseph Cotropia, of BioClonetics, Dallas, TX, whose brother Charles Cotropia, a seeasoned patent lawyer, defended him at this Hearing, and won the Case. When BioClonetics merged with Enzolytics in Dec. 2020, Charles Cotropia was appointed CEO of the Company. Currently being tested to work synergistically with ITV-1, Clone3 is the only all-human-all-natural monoclonal antibody cure for infectious diseases, including COVID & HIV-AIDS.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.